Niagen Bioscience, Inc. NAGE
1.87 USD -0.07 (-3.61%)
Regular-session close
1.86 -0.01 -0.53%
After hours · Nov 19, 7:47 PM ET
1.84 Day range 1.92
1.84 52-week range 7.12
- YTD
- -70.60%
- 1 year
- -72.90%
News
businesswire.com Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Aging--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,…
businesswire.com Niagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ Plus LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,…benzinga.com Freedom Broker Maintains Buy on Niagen Bioscience, Lowers Price Target to $6 Freedom Broker analyst Ilya Zubkov maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $8.5 to $6.
benzinga.com Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $7 Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $9 to $7.
benzinga.com Niagen Bioscience Q3 2026 Earnings Call Transcript Niagen Bioscience (NASDAQ:NAGE) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Niagen Bioscience Raises FY2026 Sales Guidance from $138.982M-$145.299M to $145.299M-$151.616M vs $130.410M Est Niagen Bioscience (NASDAQ:NAGE) raises FY2026 sales outlook from $138.982 million-$145.299 million to $145.299 million-$151.616 million vs $130.410 million estimate.
benzinga.com Niagen Bioscience Q3 EPS $(0.01) Misses $0.02 Estimate, Sales $27.192M Miss $32.062M Estimate Niagen Bioscience (NASDAQ:NAGE) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.02 by 150 percent. This is a 120 percent decrease over earnings of…
benzinga.com Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $9 Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $10 to $9.
